Erlotinib Recruiting Phase 2 Trials for Non-Small Cell Lung Carcinoma (NSCLC) / EGFR Gene Mutations Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02098954Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers